Yoshishige Samukawa

1.2k citations

25 papers · 918 indexed · 1 hit paper · h-index 13

Endocrinology, Diabetes and Metabolism top 2%
Molecular Biology
Surgery top 10%
Nephrology top 5%
Pharmacology top 10%

Co-authors: Soichi Sakai Atsushi Fukatsu Yutaka Seino Takashi Sasaki Junichi Yamaguchi Yukihiro Chino Yasuhiro Nakai Takeo Nakanishi
Topics: Diabetes Treatment and Management (20 papers)Metabolism, Diabetes, and Cancer (12 papers)Pancreatic function and diabetes (11 papers)
Cited by: Endocrinology, Diabetes and Metabolism Nephrology Pharmacology
Journals: PLoS ONE Drug Metabolism and Disposition Diabetes Obesity and Metabolism
Partner nations: Japan

In The Last Decade

Yoshishige Samukawa

25 papers receiving 897 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

2014 318 citations Yukihiro Chino, Yoshishige Samukawa et al. profile →

Peers

Countries citing papers authored by Yoshishige Samukawa

Since Specialization

Citations

This map shows the geographic impact of Yoshishige Samukawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshishige Samukawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshishige Samukawa more than expected).

Fields of papers citing papers by Yoshishige Samukawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshishige Samukawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshishige Samukawa. The network helps show where Yoshishige Samukawa may publish in the future.

Co-authorship network of co-authors of Yoshishige Samukawa

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshishige Samukawa. A scholar is included among the top collaborators of Yoshishige Samukawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshishige Samukawa. Yoshishige Samukawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The flavonoid Sudachitin regulates glucose metabolism via PDE inhibition 2024 ·Heliyon ·(unknown),Akihiko Taguchi,(unknown),(unknown),(unknown),(unknown),Takao Ono,Yoshishige Samukawa,Yukio Tanizawa,Yasuharu Ohta	2
2	Impact of the lipase inhibitor orlistat on the human gut microbiota 2023 ·Obesity Research & Clinical Practice ·(unknown),Hiroaki Ueno,Junki Miyamoto,Ikuo Kimura,(unknown),Hiroshi Iijima,(unknown),(unknown),Soichi Sakai,Yoshishige Samukawa,Yuri Tanaka,(unknown),Hideyuki Sakoda,Masamitsu Nakazato	11
3	Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study 2018 ·Advances in Therapy ·Kohji Shirai,Michitaka Tanaka,(unknown),Yuka Fujii,(unknown),Soichi Sakai,Yoshishige Samukawa	5
4	Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study 2018 ·Advances in Therapy ·Kohji Shirai,(unknown),Michitaka Tanaka,Yuka Fujii,(unknown),Soichi Sakai,Yoshishige Samukawa	10
5	Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment 2018 ·Clinical Pharmacology in Drug Development ·Yoshishige Samukawa,Masakazu Haneda,Yutaka Seino,Takashi Sasaki,Atsushi Fukatsu,Yusuke Kubo,Yuri Sato,Soichi Sakai	10
6	Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus 2017 ·Biological and Pharmaceutical Bulletin ·Yoshishige Samukawa,(unknown),Shi Chen,(unknown)	12
7	Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study 2017 ·Clinical Pharmacology in Drug Development ·Yoshishige Samukawa,Michio Sata,Kenichi Furihata,Toshifumi Ito,Naohiko Ueda,(unknown),Soichi Sakai,Yuji Kumagai	12
8	Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study 2016 ·Advances in Therapy ·Yoshishige Samukawa,(unknown),(unknown),(unknown),Soichi Sakai,Rimei Nishimura	6
9	Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus 2016 ·Advances in Therapy ·Hideaki Jinnouchi,(unknown),(unknown),(unknown),Soichi Sakai,Yoshishige Samukawa	12
10	Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials 2016 ·Clinical Therapeutics ·Soichi Sakai,Kohei Kaku,Yutaka Seino,Nobuya Inagaki,Masakazu Haneda,Takashi Sasaki,Atsushi Fukatsu,(unknown),Yoshishige Samukawa	38
11	Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans 2016 ·Xenobiotica ·(unknown),Masatoshi Hasegawa,(unknown),(unknown),(unknown),(unknown),Yukihiro Chino,(unknown),Soichi Sakai,Yoshishige Samukawa,Yasuhiro Nakai,Junichi Yamaguchi	15
12	Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males 2015 ·Advances in Therapy ·Takashi Sasaki,Yutaka Seino,Atsushi Fukatsu,Michito Ubukata,Soichi Sakai,Yoshishige Samukawa	10
13	Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial 2015 ·Advances in Therapy ·Takashi Sasaki,Yutaka Seino,Atsushi Fukatsu,Michito Ubukata,Soichi Sakai,Yoshishige Samukawa	18
14	Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects 2015 ·PLoS ONE ·Yuji Kumagai,Tomoko Hasunuma,Soichi Sakai,(unknown),Yoshishige Samukawa	3
15	Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus 2015 ·Clinical Therapeutics ·Masakazu Haneda,Yutaka Seino,Nobuya Inagaki,Kohei Kaku,Takashi Sasaki,Atsushi Fukatsu,(unknown),Yuri Sato,Soichi Sakai,Yoshishige Samukawa	62
16	Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in J apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study 2015 ·Diabetes Obesity and Metabolism ·Rimei Nishimura,Takeshi Osonoi,Shigeto Kanada,Hideaki Jinnouchi,Kazuo Sugio,(unknown),Michito Ubukata,Soichi Sakai,Yoshishige Samukawa	43
17	A Strategy for Assessing Potential Drug-Drug Interactions of a Concomitant Agent against a Drug Absorbed via an Intestinal Transporter in Humans 2014 ·Drug Metabolism and Disposition ·(unknown),Yasuhiro Nakai,(unknown),Saeko Uchida,Teisuke Takahashi,(unknown),(unknown),Soichi Sakai,Yoshishige Samukawa,Junichi Yamaguchi	5
18	Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial 2014 ·Advances in Therapy ·Takashi Sasaki,Yutaka Seino,Atsushi Fukatsu,Soichi Sakai,Yoshishige Samukawa	34
19	Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus 2014 ·Journal of Diabetes Investigation ·Yutaka Seino,Nobuya Inagaki,Masakazu Haneda,Kohei Kaku,Takashi Sasaki,Atsushi Fukatsu,Michito Ubukata,Soichi Sakai,Yoshishige Samukawa	48
20	Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study 2014 ·Current Medical Research and Opinion ·Yutaka Seino,Takashi Sasaki,Atsushi Fukatsu,Soichi Sakai,Yoshishige Samukawa	56

About Yoshishige Samukawa

Yoshishige Samukawa is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Surgery, having authored 25 papers that have together received 918 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (12 papers) and Pancreatic function and diabetes (11 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (759 citations), Nephrology (207 citations) and Pharmacology (138 citations). Yoshishige Samukawa has collaborated with scholars based in Japan. Frequent co-authors include Soichi Sakai, Atsushi Fukatsu, Yutaka Seino, Takashi Sasaki, Junichi Yamaguchi, Yukihiro Chino, Yasuhiro Nakai, Takeo Nakanishi, Michito Ubukata and Ikumi Tamai. Their work appears in journals such as PLoS ONE, Drug Metabolism and Disposition and Diabetes Obesity and Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact